+

ME03075B - Prolaktin receptor vezujući proteini i njihova upotreba - Google Patents

Prolaktin receptor vezujući proteini i njihova upotreba

Info

Publication number
ME03075B
ME03075B MEP-2018-146A MEP2018146A ME03075B ME 03075 B ME03075 B ME 03075B ME P2018146 A MEP2018146 A ME P2018146A ME 03075 B ME03075 B ME 03075B
Authority
ME
Montenegro
Prior art keywords
prolaktin
binding proteins
receptor binding
receptor
proteins
Prior art date
Application number
MEP-2018-146A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mark Anderson
Jieyi Wang
Archana Thakur
Debra Chao
Chung-Ming Hsieh
Qian Zhang
Edward B Reilly
Enrico L Digiammarino
Kenton L Longenecker
Russell A Judge
David A Egan
Charles W Hutchins
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ME03075B publication Critical patent/ME03075B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/86Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
    • G01S13/867Combination of radar systems with cameras
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/88Radar or analogous systems specially adapted for specific applications
    • G01S13/91Radar or analogous systems specially adapted for specific applications for traffic control
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/50Context or environment of the image
    • G06V20/56Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
    • G06V20/58Recognition of moving objects or obstacles, e.g. vehicles or pedestrians; Recognition of traffic objects, e.g. traffic signs, traffic lights or roads
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/0104Measuring and analyzing of parameters relative to traffic conditions
    • G08G1/0125Traffic data processing
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/015Detecting movement of traffic to be counted or controlled with provision for distinguishing between two or more types of vehicles, e.g. between motor-cars and cycles
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/04Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/042Detecting movement of traffic to be counted or controlled using inductive or magnetic detectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Remote Sensing (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Reproductive Health (AREA)
  • Multimedia (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MEP-2018-146A 2012-12-24 2013-12-23 Prolaktin receptor vezujući proteini i njihova upotreba ME03075B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745707P 2012-12-24 2012-12-24
PCT/US2013/077452 WO2014105810A1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof
EP13821368.1A EP2935331B1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
ME03075B true ME03075B (me) 2019-01-20

Family

ID=49956483

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-146A ME03075B (me) 2012-12-24 2013-12-23 Prolaktin receptor vezujući proteini i njihova upotreba

Country Status (28)

Country Link
US (4) US9725515B2 (me)
EP (2) EP2935331B1 (me)
JP (3) JP6382221B2 (me)
KR (1) KR20150100881A (me)
CN (1) CN105102480B (me)
AU (3) AU2013370548B2 (me)
BR (1) BR112015015289A2 (me)
CA (1) CA2896058A1 (me)
CY (1) CY1120286T1 (me)
DK (1) DK2935331T3 (me)
ES (1) ES2671506T3 (me)
HR (1) HRP20180822T1 (me)
HU (1) HUE037586T2 (me)
IL (1) IL239502B (me)
LT (1) LT2935331T (me)
ME (1) ME03075B (me)
MX (2) MX359532B (me)
NO (1) NO2968312T3 (me)
PL (1) PL2935331T3 (me)
PT (1) PT2935331T (me)
RS (1) RS57259B1 (me)
RU (2) RU2018129572A (me)
SG (1) SG11201504943QA (me)
SI (1) SI2935331T1 (me)
TR (1) TR201807416T4 (me)
TW (3) TWI646106B (me)
WO (1) WO2014105810A1 (me)
ZA (1) ZA201504803B (me)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2014105810A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
CA2929525A1 (en) 2013-11-04 2015-05-07 Pfizer Inc. Anti-efna4 antibody-drug conjugates
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
PL3218005T3 (pl) 2014-11-12 2023-05-02 Seagen Inc. Związki oddziałujące z glikanami i sposoby ich zastosowania
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6914193B2 (ja) 2015-06-24 2021-08-04 Jcrファーマ株式会社 Bdnfを含む融合蛋白質
TWI769982B (zh) 2015-06-24 2022-07-11 日商Jcr製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
ES2862425T3 (es) 2015-11-03 2021-10-07 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
WO2017083582A1 (en) * 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN106265480A (zh) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 纳米抗体阴道给药系统及制备方法和应用
KR20230114331A (ko) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
WO2018102304A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102497564B1 (ko) 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
WO2018124107A1 (ja) 2016-12-26 2018-07-05 Jcrファーマ株式会社 Bdnfを含む融合蛋白質
BR112019013202A2 (pt) * 2016-12-28 2019-12-10 Japan Chem Res formulação liofilizada
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2019011130A (es) * 2017-03-20 2019-11-05 Vaccinex Inc Tratamiento del cancer con un anticuerpo semaforina-4d en combinacion con un agente de modulacion epigenetica.
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗-prlr抗體藥物軛合物(adc)及其用途
JP7303182B2 (ja) 2017-04-21 2023-07-04 メリタス エルエルシー 糖尿病関連用途のための方法及び抗体
CA3063871A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
US11351140B2 (en) 2017-05-19 2022-06-07 J. Craig Venter Institute Resolvin mimetic antibodies and uses thereof
EP3589658A1 (en) 2017-08-03 2020-01-08 Alector LLC Anti-cd33 antibodies and methods of use thereof
IL274427B2 (en) 2017-11-07 2024-11-01 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN113226367B (zh) 2018-04-06 2025-05-06 Atyr医药公司 包括抗nrp2抗体的组合物和方法
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CA3108022A1 (en) * 2018-07-31 2020-02-06 Cullinan Mica Corp. Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2022522815A (ja) * 2019-03-12 2022-04-20 ユニバーシティ ヘルス ネットワーク Tsg-6抗体およびその用途
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
CN116063504A (zh) * 2019-07-12 2023-05-05 明济生物制药(北京)有限公司 Cldn18.2抗体及其用途
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
KR20230003580A (ko) * 2020-04-30 2023-01-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-cd79b 항체 및 키메라 항원 수용체 및 이의 사용 방법
WO2021262910A2 (en) * 2020-06-24 2021-12-30 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
KR20220082222A (ko) * 2020-12-10 2022-06-17 현대자동차주식회사 사륜 구동 전동화 차량의 변속 시 구동 제어 장치
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
BR112023022367A2 (pt) * 2021-05-04 2024-02-20 Agenus Inc Anticorpos anti-tigit e métodos de uso dos mesmos
US20240279357A1 (en) * 2021-06-18 2024-08-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
WO2023076998A1 (en) * 2021-10-27 2023-05-04 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN115353541B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 雌二醇衍生物的制备方法,中间体、其制备方法和应用
CN115417908B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 雌二醇衍生物、其制备方法、检测试剂盒及雌二醇定量检测方法
CN117694469B (zh) * 2024-02-02 2024-04-23 潍坊新希望六和饲料科技有限公司 一种改善褐壳鸡蛋蛋壳质量的饲料添加剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867187B2 (en) 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
US7507716B2 (en) 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
WO2008022295A2 (en) 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
CN102341118A (zh) 2009-02-26 2012-02-01 翁科里克斯公司 使癌干细胞可视化并消除癌干细胞的组合物和方法
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011151405A1 (en) 2010-06-04 2011-12-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014105810A1 (en) 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
CA2950155C (en) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses

Also Published As

Publication number Publication date
RU2664463C2 (ru) 2018-08-17
US9725515B2 (en) 2017-08-08
CN105102480A (zh) 2015-11-25
CA2896058A1 (en) 2014-07-03
US20170022281A1 (en) 2017-01-26
MX359532B (es) 2018-10-01
PT2935331T (pt) 2018-06-04
BR112015015289A2 (pt) 2017-08-15
LT2935331T (lt) 2018-06-25
US10184003B2 (en) 2019-01-22
RU2015130605A (ru) 2017-01-24
EP2935331A1 (en) 2015-10-28
NO2968312T3 (me) 2018-06-30
ES2671506T3 (es) 2018-06-06
IL239502B (en) 2019-11-28
PL2935331T3 (pl) 2018-07-31
EP3363817A1 (en) 2018-08-22
HRP20180822T1 (hr) 2018-08-10
ZA201504803B (en) 2020-02-26
TW201920245A (zh) 2019-06-01
JP6382221B2 (ja) 2018-08-29
US20210074147A1 (en) 2021-03-11
IL239502A0 (en) 2015-08-31
AU2013370548A1 (en) 2015-07-09
US20210312797A9 (en) 2021-10-07
TWI646106B (zh) 2019-01-01
RU2018129572A (ru) 2018-10-12
CN105102480B (zh) 2019-04-16
DK2935331T3 (en) 2018-06-06
HUE037586T2 (hu) 2018-09-28
SG11201504943QA (en) 2015-07-30
WO2014105810A1 (en) 2014-07-03
US20190153110A1 (en) 2019-05-23
TR201807416T4 (tr) 2018-06-21
CY1120286T1 (el) 2019-07-10
AU2013370548B2 (en) 2019-01-17
KR20150100881A (ko) 2015-09-02
AU2021202954A1 (en) 2021-06-03
MX382301B (es) 2025-03-13
MX2015008299A (es) 2016-02-11
TW201920283A (zh) 2019-06-01
JP2016504035A (ja) 2016-02-12
JP2018198608A (ja) 2018-12-20
EP2935331B1 (en) 2018-02-28
HK1216257A1 (en) 2016-10-28
AU2019202725A1 (en) 2019-05-16
SI2935331T1 (en) 2018-06-29
JP2020188775A (ja) 2020-11-26
US20140227294A1 (en) 2014-08-14
RS57259B1 (sr) 2018-08-31
TW201441259A (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
ME03075B (me) Prolaktin receptor vezujući proteini i njihova upotreba
IL279237A (en) Compositions of protein and antibody
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2812356T3 (da) CDIM-bindende proteiner og anvendelser deraf
DK2970464T3 (da) Anti-lag-3-bindende proteiner
HUE037700T2 (hu) OX40-hez kötõdõ ellenanyagok és felhasználásuk
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2850103T3 (da) ST2-antigenbindende proteiner
ME03512B (me) Cd47 antitijela i postupci za njihovu upotrebu
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
EP2905290A4 (en) HETERODIMER PROTEIN COMPOSITION
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112013030352A2 (pt) proteínas de ligação do receptor fc
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
CL2014003372A1 (es) Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
ME02224B (me) Antikancerski fuzioni protein
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
EP2855506A4 (en) PEPTIDE AND USE THEREOF
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载